Cost comparison

Australia vs US Clinical Trial Cost

For early-phase studies, running a trial in Australia with iNGENū typically costs 80–90% below an equivalent US CRO engagement — before Australia’s 43.5% refundable R&D tax incentive is applied.

Why the cost gap exists

The difference is structural, not a discount. Australia lets sponsors begin an early-phase trial without an IND, secures ethics approval in roughly four weeks, has lower site and per-patient costs than the United States, and returns up to 43.5% of eligible spend as a cash rebate. Stacked together, these move an early-phase program to one of the lowest effective costs of any high-quality jurisdiction — while the data remains FDA- and EMA-ready.

Australia vs United States — side by side

Factor	Australia (with iNGENū)	United States
Early-phase CRO cost	80–90% lower	Baseline
Regulatory step before first dose	No IND — HREC ethics + TGA CTN notification	FDA IND required
Typical ethics/approval timeline	~4 weeks	~30-day IND review + IRB
Government R&D rebate	Up to 43.5% refundable cash rebate	None equivalent
Data standard	ICH-GCP · 21 CFR Part 11	ICH-GCP · 21 CFR Part 11
FDA / EMA acceptance	Yes	Yes

Figures reflect iNGENū’s typical early-phase engagements; actual savings depend on study design, indication and site mix.

Illustrative worked example

Take an early-phase study budgeted at roughly US$4M with a US CRO. Delivered in Australia through iNGENū at 80–90% below that level, the CRO cost falls to a fraction of the US figure; the eligible Australian R&D spend then attracts up to a 43.5% refundable rebate on top, paid back to the sponsor as cash — even for pre-revenue biotechs. The combined effect is why sponsors routinely extend their runway by structuring early-phase work in Australia. This example is illustrative; iNGENū provides a fixed-milestone quote for your specific protocol.

Frequently asked questions

Australia vs US clinical trial cost — FAQs

How much cheaper is a clinical trial in Australia vs the US?

Running an early-phase trial in Australia with iNGENū typically costs 80–90% less than an equivalent US CRO engagement, before the 43.5% R&D tax rebate is applied.

Why is running a clinical trial in Australia so much cheaper than the US?

Lower site and per-patient costs, no IND requirement before starting, faster (~4-week) ethics approval, and the 43.5% refundable R&D tax incentive combine to cut the effective cost of an early-phase program well below the US pathway.

Is Australian clinical trial data accepted by the FDA and EMA?

Yes. Australian trials run to ICH-GCP standards and the data is routinely accepted in FDA IND/NDA and EMA submissions. iNGENū also provides FDA regulatory services to bridge Australian early-phase data into US programs.

Does lower cost mean lower quality?

No. iNGENū delivers US-tier scientific and regulatory rigour under ICH-GCP and 21 CFR Part 11, with documentation structured for FDA, EMA and MHRA submissions — the saving comes from jurisdiction and structure, not from cutting corners.

See what your study would cost in Australia

Send us your protocol and we’ll return a fixed-milestone quote and an R&D rebate estimate.

Request a proposal